Pricing Log in Create free account

Kalaris Therapeutics Inc. (KLRS) vs Mereo BioPharma Group plc - Sponsored ADR (MREO)

Kalaris Therapeutics Inc. and Mereo BioPharma Group plc - Sponsored ADR are both Biotechnology companies. Kalaris Therapeutics Inc. and Mereo BioPharma Group plc - Sponsored ADR are of similar size ($49.3M and $47.8M). Across the 8 metrics below, Kalaris Therapeutics Inc. leads on 4 and Mereo BioPharma Group plc - Sponsored ADR on 4.

Valuation

Metric KLRS MREO Biotechnology median
P/E n/m n/m 8.50
P/S n/m n/m 9.71
P/B 0.83 1.68 2.13
Price to free cash flow n/m n/m 20.82
EV/EBITDA 0.55 n/m 0.64
EV/Sales n/m n/m 9.21
Earnings yield (101.00%) (58.20%) (33.15%)
Free cash flow yield (85.89%) (53.23%) (25.50%)

Profitability

Metric KLRS MREO Biotechnology median
Gross margin 0.00% 0.00% 65.16%
Operating margin 0.00% 0.00% 0.00%
Net margin 0.00% 0.00% 0.00%
Free cash flow margin 0.00% 0.00% 0.00%
Return on equity (79.91%) (67.85%) (56.36%)
Return on assets (46.02%) (57.73%) (48.04%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric KLRS MREO Biotechnology median
Revenue growth (TTM) — — 6.02%
EPS growth (last fiscal year) 94.50% 10.16% 30.26%
Revenue growth, 5-year CAGR — — 9.41%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric KLRS MREO Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 10.98 5.88 4.72
Net debt to EBITDA 2.54 1.04 0.96

Dividend

Metric KLRS MREO Biotechnology median
Dividend yield — — 0.09%
Payout ratio — — —

Size

Metric KLRS MREO Biotechnology median
Market cap 47.83m 49.34m 135.18m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack